Thursday 16 October 2008

Buy Jubilant Org, target of Rs 397: India Capital Markets

India Capital Markets has maintained its buy rating on Jubilant Organosys with a target of Rs 397 in its October 15, 2008 research report. "Jubilant having started as a speciality chemical player, has rapidly expanded its presence through out the value chain of pharma life-cycle driven both organically as well as in-organically. Its recent acquisitions in the CRAMS space like Hollister-stier in US and Draxis in Canada has consolidated its position in the regulated markets. With its wellchanneled network into the regulated markets and its expanded capabilities in the CRAMS."

"Sales were up 52% YoY at Rs 9,405 million, driven by the Pharma & Life Sciences business which grew 59% YoY at Rs 5,858 million. Pharma & Life Sciences business contributed 62% of total sales in Q2FY09 (60% in Q2FY08). We maintain a Buy rating with a price target of Rs 397 per share (upside of 116%)," says India Capital Markets' research report.

Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Source: Moneycontrol

Posted by Harsh at 18:05

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)
DISCLAIMER: The author is not a registered stockbroker nor a registered advisor and does not give investment advice. His comments are an expression of opinion only and should not be construed in any manner whatsoever as recommendations to buy or sell a stock, option, future, bond, commodity, index or any other financial instrument at any time. While he believes his statements to be true, they always depend on the reliability of his own credible sources. The author recommends that you consult with a qualified investment advisor, one licensed by appropriate regulatory agencies in your legal jurisdiction, before making any investment decisions, and that you confirm the facts on your own before making important investment commitments.